It’s been a crucial week for AbbVie Inc. (NYSE:ABBV); here’s what analysts have to say.

February 21, 2018 - By Clifton Ray

 It's been a crucial week for AbbVie Inc. (NYSE:ABBV); here's what analysts have to say.
Investors sentiment decreased to 0.85 in 2017 Q3. Its down 0.15, from 1 in 2017Q2. It is negative, as 55 investors sold AbbVie Inc. shares while 640 reduced holdings. 132 funds opened positions while 462 raised stakes. 1.06 billion shares or 1.89% more from 1.04 billion shares in 2017Q2 were reported.
Tradewinds Cap Mngmt Limited Liability Corporation reported 2,270 shares or 0.1% of all its holdings. Sawgrass Asset Management Ltd reported 592,407 shares. Raymond James Financial owns 1.13M shares for 0.64% of their portfolio. Geode Management Ltd Liability Corp holds 15.35M shares or 0.5% of its portfolio. Beacon Gru holds 0.21% of its portfolio in AbbVie Inc. (NYSE:ABBV) for 12,780 shares. Tealwood Asset Mgmt Inc has 3.38% invested in AbbVie Inc. (NYSE:ABBV) for 106,025 shares. Bell Commercial Bank stated it has 0.36% of its portfolio in AbbVie Inc. (NYSE:ABBV). First Bank & Trust Of Mount Dora Trust Investment Services holds 60,465 shares or 2.64% of its portfolio. 58,491 were accumulated by Bender Robert And Assoc. Perella Weinberg Ptnrs Capital Management Limited Partnership holds 22,624 shares. Livforsakringsbolaget Skandia Omsesidigt has 88,447 shares. Next Finance Gru Inc invested in 18,564 shares or 0.47% of the stock. Palo Cap Inc holds 0.15% or 3,115 shares. Great Lakes Advsrs Ltd Com holds 0.96% or 458,527 shares. Cornerstone Advsrs, Washington-based fund reported 2,793 shares.

Since September 11, 2017, it had 0 buys, and 5 sales for $25.59 million activity. 8,300 shares were sold by SALEKI-GERHARDT AZITA, worth $705,655. 6,699 shares were sold by Michael Robert A., worth $589,512 on Thursday, September 28. Gosebruch Henry O sold $1.66 million worth of AbbVie Inc. (NYSE:ABBV) on Monday, October 30. Schumacher Laura J had sold 145,510 shares worth $14.07 million.

AbbVie Inc. (NYSE:ABBV) Ratings Coverage

Among 21 analysts covering Abbvie Inc (NYSE:ABBV), 10 have Buy rating, 2 Sell and 9 Hold. Therefore 48% are positive. Abbvie Inc had 78 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was downgraded by Leerink Swann on Monday, January 29 to “Hold”. Jefferies maintained AbbVie Inc. (NYSE:ABBV) rating on Thursday, May 25. Jefferies has “Buy” rating and $9000 target. The rating was initiated by Raymond James with “Outperform” on Friday, September 2. As per Monday, July 17, the company rating was maintained by Jefferies. The rating was maintained by Leerink Swann on Tuesday, December 5 with “Buy”. UBS downgraded AbbVie Inc. (NYSE:ABBV) on Monday, September 25 to “Neutral” rating. The stock of AbbVie Inc. (NYSE:ABBV) earned “Buy” rating by Jefferies on Monday, May 29. The rating was upgraded by Morgan Stanley to “Overweight” on Monday, November 2. Leerink Swann maintained AbbVie Inc. (NYSE:ABBV) on Monday, October 30 with “Outperform” rating. The stock has “Neutral” rating by UBS on Friday, October 13. Below is a list of AbbVie Inc. (NYSE:ABBV) latest ratings and price target changes.

02/02/2018 Broker: Argus Research Rating: Buy Old Target: $120 New Target: $145 Maintain
30/01/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $99 New Target: $131 Maintain
30/01/2018 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Underperform Old Target: $84 Downgrade
29/01/2018 Broker: Credit Suisse Rating: Hold New Target: $135.0 Maintain
29/01/2018 Broker: Leerink Swann Rating: Hold Downgrade
26/01/2018 Broker: Jefferies Rating: Buy New Target: $150.0 Maintain
26/01/2018 Broker: Cowen & Co Rating: Buy New Target: $130.0 Maintain
16/01/2018 Broker: Jefferies Rating: Buy New Target: $130.0 Maintain
04/01/2018 Broker: Jefferies Rating: Buy New Target: $120.0 Maintain
05/12/2017 Broker: Leerink Swann Rating: Buy New Target: $106.0 Maintain

The stock increased 0.74% or $0.87 during the last trading session, reaching $118.85. About 3.58M shares traded. AbbVie Inc. (NYSE:ABBV) has risen 10.63% since February 21, 2017 and is uptrending. It has underperformed by 6.07% the S&P500.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company has market cap of $188.73 billion. The firm offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It has a 36.02 P/E ratio. It also provides Kaletra, an anti- human immunodeficiency virus-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants.

More notable recent AbbVie Inc. (NYSE:ABBV) news were published by: Fool.com which released: “Did AbbVie, Inc. Just Become the Most Shareholder-Friendly Stock in America?” on February 16, 2018, also Seekingalpha.com with their article: “AbbVie’s New Capital Return Program And How It Impacts Expected Total Returns” published on February 16, 2018, Seekingalpha.com published: “AbbVie’s Bright Future” on January 30, 2018. More interesting news about AbbVie Inc. (NYSE:ABBV) were released by: Fool.com and their article: “Is AbbVie or Gilead Sciences Stock a Better Buy?” published on February 19, 2018 as well as Fool.com‘s news article titled: “3 More Reasons to Buy AbbVie Stock” with publication date: February 20, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.